Efficacy and Safety of the New Appetite Suppressant, Liraglutide: A Meta-Analysis of Randomized Controlled Trials

Background Obesity is a chronic disease associated with metabolic diseases such as diabetes and cardiovascular disease. Since the U.S. Food and Drug Administration approved liraglutide as an anti-obesity drug for nondiabetic patients in 2014, it has been widely used for weight control in overweight...

Full description

Bibliographic Details
Main Authors: Shinje Moon, Jibeom Lee, Hye Soo Chung, Yoon Jung Kim, Jae Myung Yu, Sung Hoon Yu, Chang-Myung Oh
Format: Article
Language:English
Published: Academya Publishing Co. 2021-06-01
Series:Endocrinology and Metabolism
Subjects:
Online Access:http://www.e-enm.org/upload/pdf/enm-2020-934.pdf